Clinical Conducter CTMS and OpenClinica are pleased to announce the formation of a strategic partnership
Clinical Conductor CTMS, the leading clinical trial management system, and OpenClinica, one of the world's most widely adopted electronic data capture (EDC) software platforms, are pleased to announce the formation of a strategic partnership to deliver a seamless EDC-CTMS integration to drive productivity in clinical research. With this newly formed partnership, Clinical Conductor CTMS and OpenClinica are solidifying several years of informal collaboration and bringing exciting changes to the respective CTMS and EDC applications.
Beginning immediately, Clinical Conductor CTMS will begin offering the OpenClinica Enterprise Edition EDC as part of its product offerings for clinical research management. This integrated solution offers a seamless trial and data management experience. The integrated systems exchange critical information pertaining to patient details, study protocols, CRFs, and more. The result is faster study execution, more accurate trial management and streamlined clinical research operations.
“We have seen a significant shift in recent years in the complexity of clinical research and the amount of collaboration that needs to go on between researchers in order for a trial to be successful,” said Dan Kerpelman, CEO of Bio-Optronics, the maker of Clinical Conductor. “In order to meet the changing needs of the research marketplace, we sought out a partner who shared the same core values as us for helping researchers conduct the best possible research and improve operations. We found that partner in OpenClinica. The technology flexibility, years of experience, and track record of excellence in clinical research makes OpenClinica an ideal fit for Clinical Conductor CTMS and an exciting new offering for the clinical research industry as a whole.”
According to OpenClinica CEO, Cal Collins, “CTMS and EDC are two sides of the same coin. Having high-quality, real-time clinical data improves decision making and operational efficiency--you get higher quality clinical data faster when sites and sponsors are operationally on the same page. This joint solution will allow users to reduce redundancy, obtain direct access to high-quality data, and make decisions faster. The Clinical Conductor team’s deep domain experience and commitment to providing world-class customer support made partnering with them a clear choice.”
Clinical Conductor and OpenClinica represent the largest install bases in their respective categories of CTMS and EDC. “By utilizing both Clinical Conductor CTMS and OpenClinica, researchers benefit from two best-of-breed companies, providing an advantage over individual companies who try and do it all, but end up being not great in any category,” added Collins.
Additionally, current users of both the OpenClinica Community Edition and OpenClinica Enterprise Edition EDC will be able to benefit from the OpenClinica-Clinical Conductor CTMS integration.
“We are excited to be able to offer this integrated solution to both our institutional and non-institutional clients alike that are in need of a fully integrated system to help them manage not only their research administration, but now also the clinical data itself,” said Sergio Armani, Director of Business Development at Bio-Optronics. “While Clinical Conductor will continue to integrate with multiple different EDCs, many clients have been asking us for a complete, integrated solution. We are now able to deliver this.”
The partnership will also allow both companies’ engineering teams to work closely together to create even deeper levels of integration. As the partnership continues to expand and grow, additional exciting developments will be announced.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.